- Previous Close
7.50 - Open
7.59 - Bid 6.93 x 100
- Ask 7.01 x 100
- Day's Range
6.33 - 7.73 - 52 Week Range
6.33 - 12.38 - Volume
498,774 - Avg. Volume
152,776 - Market Cap (intraday)
349.661M - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
-- - EPS (TTM)
-1.73 - Earnings Date May 9, 2025 - May 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.83
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
www.aurabiosciences.comRecent News: AURA
View More
Performance Overview: AURA
Trailing total returns as of 3/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AURA
View MoreValuation Measures
Market Cap
349.66M
Enterprise Value
194.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.22%
Return on Equity (ttm)
-50.99%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-83.22M
Diluted EPS (ttm)
-1.73
Balance Sheet and Cash Flow
Total Cash (mrq)
174.38M
Total Debt/Equity (mrq)
10.93%
Levered Free Cash Flow (ttm)
-47.35M
Research Analysis: AURA
View MoreCompany Insights: AURA
AURA does not have Company Insights
Research Reports: AURA
View MoreDaily – Vickers Top Buyers & Sellers for 11/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/10/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.